Stockscreener 앱 받기
150.54
1.29%
-1.66
전일 마감가:
$152.20
열려 있는:
$150.78
하루 거래량:
4.43M
Relative Volume:
0.43
시가총액:
$371.22B
수익:
$65.51B
순이익/손실:
$8.93B
주가수익비율:
42.37
EPS:
3.5532
순현금흐름:
$14.12B
1주 성능:
+10.83%
1개월 성능:
+20.76%
6개월 성능:
+22.88%
1년 성능:
+77.45%
1일 변동 폭
$148.52
$151.43
1주일 범위
$133.40
$153.50
52주 변동 폭
$77.58
$153.50
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
150.47 | 375.50B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,262.94 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.59 | 658.89B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.73 | 470.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
157.34 | 304.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-02-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-08 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-10-13 | 재개 | Citigroup | Neutral |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Merck & Co., Inc. (NYSE:MRK) Downgraded to "Sector Perform" Rating by Royal Bank Of Canada - MarketBeat
This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Merck & Co., Inc. (NYSE:MRK) Raised to Overweight at Morgan Stanley - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Stock Rating Lowered by Jefferies Financial Group - MarketBeat
Morgan Stanley Upgrades Merck & Co. to Overweight From Equalweight, Adjusts PT to $179 From $116 - marketscreener.com
Jennison Associates LLC Has $350.67 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Holdings Trimmed by Hohimer Wealth Management LLC - MarketBeat
Hodges Capital Management Inc. Sells 8,148 Shares of Merck & Co., Inc. $MRK - MarketBeat
Massachusetts Financial Services Co. MA Reduces Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. stock jumps to record high as cancer vaccine data eases Keytruda risk - Ad-hoc-news.de
Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today? - TradingView
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial GainsPfizer (NYSE:PFE), Mode - Benzinga
MRNA, BULL, BMNR, MSTR, MRK: 5 Trending Stocks TodayModerna (NASDAQ:MRNA) - Benzinga
Shareholders that lost money on Merck & Co., Inc.(MRK) should con - The National Law Review
Why Moderna Stock Skyrocketed Today - The Motley Fool
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy? - Finviz
Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In FocusMerck & Co (NYSE:MRK) - Benzinga
Merck & Co Inc (MRK) Stock Up 12.6% but GF Value Says Overvalued -- GF Score: 72/100 - GuruFocus
Merck's Large Late-Stage Pipeline Is Building Solid Defense Against Keytruda's Patent Cliff - Morningstar
Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions - Benzinga
Pfizer Stock Rises Wednesday: What's Going On? - Benzinga
Stock Traders Buy High Volume of Merck & Co., Inc. Call Options (NYSE:MRK) - MarketBeat
Huge Unusual Put Options Volume in MerckIs MRK Stock Overvalued? - Barchart.com
MERCK CO INC - Financial Post
Merck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead (NYSE:MRK) - Seeking Alpha
Merck: Why Consolidation Looks Like The Next Move (Rating Downgrade) (NYSE:MRK) - Seeking Alpha
Merck stock hits a new 52-week high on melanoma data - Ad-hoc-news.de
Moderna's Cancer Vaccine Win Is Merck's Story Too - Benzinga
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results - Reuters
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday - Benzinga
Merck & Co Inc Stock (MRK) Opened Up by 8.82% on Aug 19: Key Drivers Unveiled - tradingkey.com
Moderna, Merck surge on positive trial results for melanoma vaccine - Sharecast.com
Merck and Moderna Release Landmark Personalized Cancer Therapy Trial Success, Stocks Soar - Benzinga
Merck, Moderna say melanoma vaccine meets goals in large trial - Reuters
Narwhal Capital Management Reduces Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Vest Financial LLC - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by D.A. Davidson & CO. - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Sets New 12-Month HighHere's What Happened - MarketBeat
Benjamin Edwards Inc. Boosts Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck stock holds firm as Q2 sales hit $16.61 billion - AD HOC NEWS
Merck stock hits a record high. Investors track valuation and growth - AD HOC NEWS
Cisco, Merck, Cheniere Energy And More: CNBC’s ‘Final Trades’ - Benzinga
Merck & Co. Inc. Invests $9.04 Billion in Sutro Biopharma, Inc. $STRO - MarketBeat
Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc. - MarketBeat
What Is Driving Interest in Merck & Co. (NYSE:MRK) as Pharmaceutical Deals Keep Flowing? - Kalkine Media
Munich Reinsurance Co Stock Corp in Munich Grows Stake in Merck & Co., Inc. $MRK - MarketBeat
Mizuho Markets Cayman LP Invests $960,000 in Merck & Co., Inc. $MRK - MarketBeat
Resilient Merck stock holds close to a 12-month high on oncology strength - AD HOC NEWS
Merck (NYSE: MRK): What Could Drive Its Next Phase? - Kalkine Media
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
자본화:
|
볼륨(24시간):